Oct 15 (Reuters) - The US FDA on Thursday warned of a potentially high-risk issue involving certain Edwards Lifesciences EW.N delivery systems used in transcatheter mitral valve replacement after one death and one serious injury.
The FDA said Edwards Lifesciences had asked customers to remove affected devices from use and return impacted products.
Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
